Longer life expectancy with less risk of premature death from heart disease, stroke, diabetes, and other obesity-related conditions
Significant Weight Loss Potential : Clinical trials reveal average weight losses ranging from 13 to 22 lbs over time
Patients experienced symptoms such as shortness of breath, chest pain, fatigue, and heart murmurs
however we cannot establish causality based on these retrospective results and further prospective investigations are needed. In the second study, researchers focused on examining how GLP-1 use might impact the risk of developing osteoporosis, gout, or osteomalacia (bone softening) in people with type 2 diabetes and obesity
Real-world evidence supporting Tandem Control-IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations